Intestinal failure-associated liver disease: Causes, manifestations and therapies

Fedja A. Rochling, Hilary A. Catron

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Purpose of reviewThe goal of this review is to provide updates on the causes, manifestations and therapies IFALD in adults with an emphasis on recent discoveries on pathways of pathogenesis and interventions to reduce the incidence of IFALD.Recent findingsIFALD is a multifactorial complication of long-term home parenteral therapy. Although exact pathways are unknown, altered bile acid metabolism, microbiome dysbiosis impact on the gut-liver axis and soybean-based lipid formulations are major drivers of IFALD development.SummaryIFALD contributes to morbidity and mortality in patients on parenteral nutrition. Proactive management by a multidisciplinary team has led to improved outcomes in at-risk patients. Attention to early treatment and prevention of sepsis, introduction of nonsoybean based lipid formulations, surgical procedures such as step enteroplasties and, potentially, microbiome dysbiosis are considerations in IFLAD management.

Original languageEnglish (US)
Pages (from-to)126-133
Number of pages8
JournalCurrent opinion in gastroenterology
Volume35
Issue number2
DOIs
StatePublished - Mar 1 2019

Fingerprint

Dysbiosis
Liver Diseases
Microbiota
Lipids
Parenteral Nutrition
Bile Acids and Salts
Soybeans
Sepsis
Therapeutics
Morbidity
Mortality
Liver
Incidence

Keywords

  • intestinal failure-associated liver disease
  • microbiome
  • parenteral nutrition
  • short bowel syndrome

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Intestinal failure-associated liver disease : Causes, manifestations and therapies. / Rochling, Fedja A.; Catron, Hilary A.

In: Current opinion in gastroenterology, Vol. 35, No. 2, 01.03.2019, p. 126-133.

Research output: Contribution to journalReview article

@article{d2f75ee94e264c67bd4c9c974ef71a50,
title = "Intestinal failure-associated liver disease: Causes, manifestations and therapies",
abstract = "Purpose of reviewThe goal of this review is to provide updates on the causes, manifestations and therapies IFALD in adults with an emphasis on recent discoveries on pathways of pathogenesis and interventions to reduce the incidence of IFALD.Recent findingsIFALD is a multifactorial complication of long-term home parenteral therapy. Although exact pathways are unknown, altered bile acid metabolism, microbiome dysbiosis impact on the gut-liver axis and soybean-based lipid formulations are major drivers of IFALD development.SummaryIFALD contributes to morbidity and mortality in patients on parenteral nutrition. Proactive management by a multidisciplinary team has led to improved outcomes in at-risk patients. Attention to early treatment and prevention of sepsis, introduction of nonsoybean based lipid formulations, surgical procedures such as step enteroplasties and, potentially, microbiome dysbiosis are considerations in IFLAD management.",
keywords = "intestinal failure-associated liver disease, microbiome, parenteral nutrition, short bowel syndrome",
author = "Rochling, {Fedja A.} and Catron, {Hilary A.}",
year = "2019",
month = "3",
day = "1",
doi = "10.1097/MOG.0000000000000503",
language = "English (US)",
volume = "35",
pages = "126--133",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Intestinal failure-associated liver disease

T2 - Causes, manifestations and therapies

AU - Rochling, Fedja A.

AU - Catron, Hilary A.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Purpose of reviewThe goal of this review is to provide updates on the causes, manifestations and therapies IFALD in adults with an emphasis on recent discoveries on pathways of pathogenesis and interventions to reduce the incidence of IFALD.Recent findingsIFALD is a multifactorial complication of long-term home parenteral therapy. Although exact pathways are unknown, altered bile acid metabolism, microbiome dysbiosis impact on the gut-liver axis and soybean-based lipid formulations are major drivers of IFALD development.SummaryIFALD contributes to morbidity and mortality in patients on parenteral nutrition. Proactive management by a multidisciplinary team has led to improved outcomes in at-risk patients. Attention to early treatment and prevention of sepsis, introduction of nonsoybean based lipid formulations, surgical procedures such as step enteroplasties and, potentially, microbiome dysbiosis are considerations in IFLAD management.

AB - Purpose of reviewThe goal of this review is to provide updates on the causes, manifestations and therapies IFALD in adults with an emphasis on recent discoveries on pathways of pathogenesis and interventions to reduce the incidence of IFALD.Recent findingsIFALD is a multifactorial complication of long-term home parenteral therapy. Although exact pathways are unknown, altered bile acid metabolism, microbiome dysbiosis impact on the gut-liver axis and soybean-based lipid formulations are major drivers of IFALD development.SummaryIFALD contributes to morbidity and mortality in patients on parenteral nutrition. Proactive management by a multidisciplinary team has led to improved outcomes in at-risk patients. Attention to early treatment and prevention of sepsis, introduction of nonsoybean based lipid formulations, surgical procedures such as step enteroplasties and, potentially, microbiome dysbiosis are considerations in IFLAD management.

KW - intestinal failure-associated liver disease

KW - microbiome

KW - parenteral nutrition

KW - short bowel syndrome

UR - http://www.scopus.com/inward/record.url?scp=85060629831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060629831&partnerID=8YFLogxK

U2 - 10.1097/MOG.0000000000000503

DO - 10.1097/MOG.0000000000000503

M3 - Review article

C2 - 30585838

AN - SCOPUS:85060629831

VL - 35

SP - 126

EP - 133

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 2

ER -